MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Ligand Pharmaceuticals Incorporated Operating Cash Flow 2011-2026 | LGND
Annual Operating Cash Flow Ligand Pharmaceuticals Incorporated
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 97 M | 49.6 M | 138 M | 78.8 M | 54.6 M | -29.3 M | 194 M | 88.6 M | 60.7 M | 41.7 M | 20.6 M | 20.7 M | 161 K | -1.17 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 194 M | -29.3 M | 58.1 M |
Quarterly Operating Cash Flow Ligand Pharmaceuticals Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -25.4 M | - | - | - | 18.7 M | - | - | - | 33.9 M | - | 84.4 M | 63.9 M | 52 M | - | 51.2 M | 31.1 M | 10.8 M | - | 54 M | 41.3 M | 16.9 M | - | -22 M | -15.8 M | 45.3 M | - | 161 M | 134 M | 60.8 M | - | 57.3 M | 29.6 M | 19.2 M | - | 42 M | 23.5 M | 13.1 M | - | 28.1 M | 17.6 M | 7.58 M | - | 10.3 M | 6.58 M | 2.58 M | - | 8.66 M | 9.02 M | 2.08 M | - | -2.01 M | -1.1 M | -369 K | - | -8.19 M | -7.13 M | 911 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 161 M | -25.4 M | 27.1 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B |  France |
 |
Autolus Therapeutics plc
AUTL
|
-284 M | $ 1.34 | -3.6 % | $ 357 M |  Britain |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K |  USA |
 |
DBV Technologies S.A.
DBVT
|
-121 M | $ 20.13 | -1.13 % | $ 2.81 B | France |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.65 | 1.3 % | $ 8.78 B |  Australia |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Dyadic International
DYAI
|
-5.7 M | $ 0.87 | - | $ 31.5 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
-1.94 M | $ 2.57 | -3.57 % | $ 16.1 M | USA |
 |
Equillium
EQ
|
-22.7 M | $ 2.04 | 1.24 % | $ 117 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
Fate Therapeutics
FATE
|
-106 M | $ 1.13 | -5.04 % | $ 134 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Forte Biosciences
FBRX
|
-50.9 M | $ 26.57 | 0.49 % | $ 344 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-12.5 M | $ 6.14 | -4.36 % | $ 175 M | USA |
|
Foghorn Therapeutics
FHTX
|
-86.1 M | $ 4.74 | -2.87 % | $ 299 M | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
33.1 M | $ 14.46 | 0.03 % | $ 4.46 B | USA |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Fulcrum Therapeutics
FULC
|
-60.1 M | $ 7.55 | -3.58 % | $ 478 K | USA |
 |
Galectin Therapeutics
GALT
|
-23.9 M | $ 2.25 | -12.3 % | $ 144 M | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
890 M | $ 87.65 | -3.98 % | $ 27.2 B | Germany |
 |
Gilead Sciences
GILD
|
10 B | $ 138.19 | -1.38 % | $ 172 B | USA |
 |
Coherus BioSciences
CHRS
|
-139 M | $ 1.61 | -3.59 % | $ 189 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-10.6 M | $ 3.5 | -1.13 % | $ 236 B | Britain |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-5.88 M | $ 0.54 | 4.26 % | $ 503 K |  Israel |
 |
Genmab A/S
GMAB
|
1.33 B | $ 27.01 | -2.67 % | $ 17.2 B |  Danmark |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
524 M | $ 314.44 | -4.81 % | $ 41.2 B | USA |
 |
Gossamer Bio
GOSS
|
-171 M | $ 0.32 | -7.11 % | $ 73.1 M | USA |
 |
Grifols, S.A.
GRFS
|
597 M | $ 7.91 | -3.95 % | $ 6.83 B |  Spain |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
GT Biopharma
GTBP
|
-12.9 M | $ 0.42 | -6.49 % | $ 2.32 M | USA |
 |
Aileron Therapeutics
ALRN
|
-19.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Halozyme Therapeutics
HALO
|
652 M | $ 63.51 | 0.68 % | $ 7.61 B | USA |
 |
Burford Capital Limited
BUR
|
181 M | $ 4.42 | -1.34 % | $ 727 M | Britain |